SELLAS Life Sciences Group, Inc.
Close on Oct 19, 2026
- Market cap
- $1.98B
- P/E (TTM)
- –
- Dividend yield
- –
About SELLAS Life Sciences
Pharmaceutical Preparations, SIC 2834
The company is a late-stage clinical biopharmaceutical enterprise dedicated to developing innovative treatments for multiple cancer indications. Its development pipeline centers on two main product candidates: galinpepimut-S (GPS), a targeted peptide immunotherapy engineered against the WT1 antigen, and SLS009 (tambiciclib), a selective small molecule CDK9 inhibitor. The business evaluates these investigational therapies for hematologic malignancies such as acute myeloid leukemia, multiple myeloma, and lymphoma, as well as various solid tumors. Its ultimate prospective end-users are cancer patients requiring novel therapeutic interventions, while its operational partners include healthcare institutions, research networks, and biotechnology collaborators licensed for regional commercialization.
The organization's clinical trials operate across multiple international regions, including North America, Europe, and Asia. Its lead Phase 3 study spans approximately 95 clinical trial sites, alongside broader collaborative clinical networks connecting research centers and hospitals across Europe and mainland China. The provided text contains no mention of company headquarters.
Summary of the business section of SELLAS Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SELLAS Life Sciences Group, Inc.
- Founded
- 2006
- Headquarters
- New York, NY
- Address
- 7 Times Square, Suite 2503 10036
- Phone
- (646) 200-5278
- Website
- galenabiopharma.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, San Jose, California
Stock & identifiers
- Ticker
- SLS
- Exchange
- Nasdaq
- IPO date
- Mar 12, 2008
- Shares outstanding
- 202M, Aug 10, 2026
- Public float
- $219.13M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Nov 8, 2019; 1-for-50 reverse, Nov 7, 2019; 1-for-30 reverse, Jan 2, 2018; 1-for-20 reverse, Mar 15, 2017; 1-for-20 reverse, Nov 14, 2016
- SEC CIK
- 1390478
- CUSIP
- 81642T209
- ISIN
- US81642T2096
- LEI
- 549300VZIH50VYURLQ98
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Angelos M. Stergiou | President and CEO, Director | 1,976,604 |
| John Thomas Burns | CFO | 609,254 |
| Dragan Cicic | SVP, Chief Development Officer | 557,805 |
| David A. Scheinberg | Director | 73,082 |
| Nostrand Robert L. Van | Director | 82,900 |
| Katherine Bach Kalin | Director | 154,400 |
| John Varian | Director | 72,900 |
| Jane Wasman | Director | 92,900 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Stergiou | $1.88M | $4.43M | $975.72K | $160 | – |
| FY2024 Dr.Stergiou | $1.19M | $1.33M | $697.13K | $44 | – |
| FY2023 Dr.Stergiou | $1.75M | $801.28K | $855.81K | $45 | – |
| FY2022 Dr.Stergiou | $1.95M | $667.30K | $995.22K | $43 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had 13 full-time employees.”
Corporate history
Events identified from SEC filings